SAB Biotherapeutics Inc — Quarterly Financial Statistics (NASDAQ:SABS) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities -6.29 M-9.53 M-7.8 M-7.15 M-13.05 M -37.53 M Cash from investing activities -1.15 M9.33 M4.67 M5.2 M-129.87 M -110.67 M Cash from financing activities -674.13 K216.96 K-173.98 K-173.84 K168.69 M 168.56 M Free cash flow -6.39 M-9.59 M-7.8 M-7.15 M-13.05 M -37.59 M

Nouvelles

L’action de SAB Biotherapeutics reçoit une recommandation d’achat de UBS

SAB Biotherapeutics stock initiated with Buy rating at UBS on diabetes drug potential

Guggenheim initie la couverture de SAB Biotherapeutics avec une recommandation d’achat

Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential

SAB Biotherapeutics réduit la taille de son conseil d’administration suite à la démission de deux administrateurs

SAB Biotherapeutics reduces board size following resignations of two directors

Les actionnaires de SAB Biotherapeutics approuvent la modification du plan d’actions et la proposition de conversion des actions de série B

SAB Biotherapeutics shareholders approve equity plan amendment and Series B conversion proposal

SAB Biotherapeutics conserve sa note d’achat chez H.C. Wainwright après des données positives sur son traitement du diabète

SAB Biotherapeutics stock maintains Buy rating at H.C. Wainwright on positive diabetes treatment data

Chardan Capital lowers SAB Biotherapeutics stock price target to $12 from $20

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release